Medical professionals are often proponents of preventive medicine. Stop it before it starts, they frequently say. Still, how do they fix a problem which is the inevitable result of another problem, like an adhesion? This is difficult to determine, particularly if the primary procedure leaves a scar in a place where, ideally, it should not occur.
Cardiovascular Sciences Inc., a medical products development company, is working toward offering product solutions for these surgical adhesion issues. An adhesion is the fusing of skin or internal tissues as a result of surgery. These adhesions create scarring. If the scar is of a certain size, in a certain location, or of a certain type, it can cause serious issues after the surgery as recovery commences. In this sense, “serious issues” means growing back together in a way not conducive to proper body mechanics, like fluid metabolism or joint flexibility.
Cardiovascular Sciences Inc. came to this portion of the medical products marketplace after culling the marketplace for medical products that might provide a significant and reliable revenue stream while also providing a viable medical benefit. After researching the marketplace, the company feels that its opportunity for consistent revenue and product development lies in the adhesion products marketplace.
With a solid management team and researchers in place, the company has acquired intellectual property rights for several processes. The intellectual rights obtained are considered key steps to meeting the company’s time frame of 12-18 months to the veterinary care marketplace, a marketplace chosen for its less stringent entry requirements and reliable market size (approximately $500 million worldwide).
As veterinary markets are entered, the company plans to pursue the process of entry into the human marketplace for these types of products. Along with its University of Central Florida Research partner, the company feels confident that it will be able to garner a significant portion of the $3 billion domestic /$5 billion worldwide market for these types of products.
Given that the company has settled on this product category after researching a fairly lengthy list of possible medical sectors to develop, it is likely that their focus and dedication to meeting timelines assures success. Management appears to have a fairly extensive background in the area under consideration, and surgical adhesions are not likely to become a thing of the past. As these products are offered to the marketplace, they may well become standard operating procedure.
Let us hear your thoughts below: